Kevin P. Charpentier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kevin P. Charpentier has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Brody Winn
Department of Pathology, Rode Island Hospital and the Warren Alpert School of Medicine at Brown University, Providence, RI, USA
2 shared publications- Damian E. Dupuy
Rhode Island Hospital (United States)
2 shared publications Farrah Wolf
Department of Radiology, Rode Island Hospital and the Warren Alpert School of Medicine at Brown University, Providence, RI, USA
2 shared publicationsLelia Noble
Department of Pathology, Rode Island Hospital and the Warren Alpert School of Medicine at Brown University, Providence, RI, USA
2 shared publicationsMurray Resnick
Department of Pathology, Rode Island Hospital and the Warren Alpert School of Medicine at Brown University, Providence, RI, USA
2 shared publicationsAlan A. Thomay
Department of Surgery, The Alpert Medical School, Brown University, Rhode Island Hospital, Providence, Rhode Island, USA
1 shared publication
Latest Publications
- 23 August 2010
- Published by Wiley in Journal of Surgical Oncology
- Vol. 102 (8) , 1002-1008
Optimizing resection for “responding” hepatic metastases after neoadjuvant chemotherapy
Fifty percent of patients with colorectal cancer will develop metastases at some time during their disease, with the liver being the most common site. Recent advances in the treatment of metastatic colorectal cancer have led to a change in treatment paradigm. What follows is a review of the surgical management of hepatic colorectal metastases responding to neoadjuvant chemotherapy. In addition, the complexity of treating patients with “disappearing” colorectal liver metastases is discussed. J. Surg. Oncol. 2010;102:1002–1008.
- 23 August 2010
- Published by Wiley in Journal of Surgical Oncology
- Vol. 102 (8) , 1002-1008
Optimizing resection for “responding” hepatic metastases after neoadjuvant chemotherapy
Fifty percent of patients with colorectal cancer will develop metastases at some time during their disease, with the liver being the most common site. Recent advances in the treatment of metastatic colorectal cancer have led to a change in treatment paradigm. What follows is a review of the surgical management of hepatic colorectal metastases responding to neoadjuvant chemotherapy. In addition, the complexity of treating patients with “disappearing” colorectal liver metastases is discussed. J. Surg. Oncol. 2010;102:1002–1008.
Intention to treat survival following liver transplantation for hepatocellular carcinoma within a donor service area
The optimal therapy for patients with hepatocellular carcinoma (HCC), American Liver Tumor Study Group Stage I or II remains controversial. While the five-year survival rates appear equivalent in selected patients undergoing either surgical resection or transplantation, liver transplantation appears to offer the best disease free survival [ 1 x [1] Margarit, C., Escartin, A., Castells, L., Vargas, V., Allende, E., and Bilbao, I. Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. Liver Transpl. 2005; 11: 1242–1251 Crossref | PubMed | Scopus (152) | Google Scholar See all References ] [1] . Time to transplantation is influenced by organ availability, which varies by region; therefore, the decision for transplant versus surgical resection as first line therapy should be in part based on local/regional intention to treat survival rates for both therapies. This study aimed to assess the impact of wait times on patient survival following liver transplantation for HCC in a donor specific area (DSA).
Intention to treat survival following liver transplantation for hepatocellular carcinoma within a donor service area
The optimal therapy for patients with hepatocellular carcinoma (HCC), American Liver Tumor Study Group Stage I or II remains controversial. While the five-year survival rates appear equivalent in selected patients undergoing either surgical resection or transplantation, liver transplantation appears to offer the best disease free survival [ 1 x [1] Margarit, C., Escartin, A., Castells, L., Vargas, V., Allende, E., and Bilbao, I. Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. Liver Transpl. 2005; 11: 1242–1251 Crossref | PubMed | Scopus (152) | Google Scholar See all References ] [1] . Time to transplantation is influenced by organ availability, which varies by region; therefore, the decision for transplant versus surgical resection as first line therapy should be in part based on local/regional intention to treat survival rates for both therapies. This study aimed to assess the impact of wait times on patient survival following liver transplantation for HCC in a donor specific area (DSA).
- Open Access
- 27 February 2008
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 14 (3) , 303-307
Removing patients from the liver transplant wait list: A survey of US liver transplant programs
Guidelines are in place regarding who is a candidate for liver transplantation. Once a potential candidate is listed, there are no uniform guidelines indicating when he should be removed from the list because of a change in clinical status. A survey with 14 scenarios was sent to the medical and surgical directors of all liver transplant programs in the United States. In each scenario, clinical information was provided about a patient active on the transplant wait list. Data regarding a clinical change were provided, and responders were questioned whether they would remove the patient from the wait list. The scenarios were designed to address the issues of age, etiology of liver disease, renal dysfunction, respiratory failure, infection, failure to thrive, and social support. Two hundred four questionnaires were mailed with 47 responses (23%): 8 return to sender, 24 surgeons, and 15 hepatologists. All 11 United Network for Organ Sharing regions were represented. The responders were well distributed among university programs (n = 28), private practice programs (n = 10), and health maintenance organization programs (n = 1). Nine responses were from small-volume programs (≤25 transplants), 12 were from medium-volume programs (26–50 transplants), and 18 were from large-volume programs (≥51 transplants). There was wide variability between responders regarding which patients should be removed from the transplant wait list. Patient age and etiology of liver disease led to the greatest discordance among responders. In conclusion, there is a lack of agreement and standardization among US liver transplant programs regarding who should be removed from the wait list for a change in clinical status. Liver Transpl 14:303–307, 2008. © 2008 AASLD.
- 27 February 2008
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 14 (3) , 303-307
Open AccessRemoving patients from the liver transplant wait list: A survey of US liver transplant programs
Guidelines are in place regarding who is a candidate for liver transplantation. Once a potential candidate is listed, there are no uniform guidelines indicating when he should be removed from the list because of a change in clinical status. A survey with 14 scenarios was sent to the medical and surgical directors of all liver transplant programs in the United States. In each scenario, clinical information was provided about a patient active on the transplant wait list. Data regarding a clinical change were provided, and responders were questioned whether they would remove the patient from the wait list. The scenarios were designed to address the issues of age, etiology of liver disease, renal dysfunction, respiratory failure, infection, failure to thrive, and social support. Two hundred four questionnaires were mailed with 47 responses (23%): 8 return to sender, 24 surgeons, and 15 hepatologists. All 11 United Network for Organ Sharing regions were represented. The responders were well distributed among university programs (n = 28), private practice programs (n = 10), and health maintenance organization programs (n = 1). Nine responses were from small-volume programs (≤25 transplants), 12 were from medium-volume programs (26–50 transplants), and 18 were from large-volume programs (≥51 transplants). There was wide variability between responders regarding which patients should be removed from the transplant wait list. Patient age and etiology of liver disease led to the greatest discordance among responders. In conclusion, there is a lack of agreement and standardization among US liver transplant programs regarding who should be removed from the wait list for a change in clinical status. Liver Transpl 14:303–307, 2008. © 2008 AASLD.